bms-986315
mAbexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 25, 2020 (NCT04349267)
Timeline
Indications
Mechanism of action
KLRC1 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06094296 | Phase 2 | Nov 3, 2023 | Bristol-Myers Squibb |
| NCT04349267 | Phase 1/Phase 2 (Phase 2) | Apr 25, 2020 | Bristol-Myers Squibb |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 2 | 2 | 1 | 2020 |
1 organizations
Page 1 / 1